Floatz logo

Lutetium Lu 177 Psma-10.1

Biochemically Recurrent Prostate Carcinoma

Emory UniversityradiopharmaceuticalPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

114 Active assets in the Biochemically Recurrent Prostate Carcinoma cohort.

Asset / SponsorPhaseRating
LEUPROLIDE
Mayo Clinic
Phase 4BBB
Enzalutamide
Pfizer
Phase 4BBB
PREDNISONE TABLETS
Mayo Clinic
Phase 4BBB
Degarelix
Baptist Health South Florida
Phase 3BBB
Abiraterone Acetate
Mayo Clinic
Phase 4BBB

View all 50 →

Same molecule, other indications

Lutetium Lu 177 Psma-10.1 is also rated in:

prostate adenocarcinomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →